Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.
Google ScholarÂ
Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer. Lancet. 2019;394:1467–80.
Google ScholarÂ
Eng C, Jácome AA, Agarwal R, Hayat MH, Byndloss MX, Holowatyj AN, et al. A comprehensive framework for early-onset colorectal cancer research. Lancet Oncol. 2022;23:e116–28.
Google ScholarÂ
Patel SG, Karlitz JJ, Yen T, Lieu CH, Boland CR. The rising tide of early-onset colorectal cancer: a comprehensive review of epidemiology, clinical features, biology, risk factors, prevention, and early detection. Lancet Gastroenterol Hepatol. 2022;7:262–74.
Google ScholarÂ
Li J, Ma X, Chakravarti D, Shalapour S, DePinho RA. Genetic and biological hallmarks of colorectal cancer. Genes Dev. 2021;35:787–820.
Google ScholarÂ
Wu Q, Schapira M, Arrowsmith CH, Barsyte-Lovejoy D. Protein arginine methylation: from enigmatic functions to therapeutic targeting. Nat Rev Drug Discov. 2021;20:509–30.
Google ScholarÂ
Wang F, Jin Y, Wang M, Luo H, Fang W, Wang Y, et al. Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial. Nat Med. 2024;30:1035–43.
Google ScholarÂ
Jung G, Hernández-Illán E, Moreira L, Balaguer F, Goel A. Epigenetics of colorectal cancer: biomarker and therapeutic potential. Nat Rev Gastroenterol Hepatol. 2020;17:111–30.
Google ScholarÂ
Cheng Y, He C, Wang M, Ma X, Mo F, Yang S, et al. Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials. Signal Transduct Target Ther. 2019;4:62.
Google ScholarÂ
Yang L, Ma D, Cao Y, Li D, Zhou X, Feng J, et al. PRMT5 functionally associates with EZH2 to promote colorectal cancer progression through epigenetically repressing CDKN2b expression. Theranostics. 2021;11:3742–59.
Google ScholarÂ
Tong Y, Wang F, Li S, Guo W, Li Q, Qian Y, et al. Histone methyltransferase KMT5C drives liver cancer progression and directs therapeutic response to PARP inhibitors. Hepatology. 2024;80:38–54.
Google ScholarÂ
Hou Y, Liu W, Yi X, Yang Y, Su D, Huang W, et al. PHF20L1 as a H3K27me2 reader coordinates with transcriptional repressors to promote breast tumorigenesis. Sci Adv. 2020;6:eaaz0356.
Google ScholarÂ
She X, Wu Q, Rao Z, Song D, Huang C, Feng S, et al. SETDB1 methylates MCT1 promoting tumor progression by enhancing the lactate shuttle. Adv Sci. 2023;10:e2301871.
Google ScholarÂ
Peng Z, Fang W, Wu B, He M, Li S, Wei J, et al. Targeting smurf1 to block PDK1-Akt signaling in KRAS-mutated colorectal cancer. Nat Chem Biol. 2025;21:59–70.
Google ScholarÂ
Hou Z, Sun L, Xu F, Hu F, Lan J, Song D, et al. Blocking histone methyltransferase SETDB1 inhibits tumorigenesis and enhances cetuximab sensitivity in colorectal cancer. Cancer Lett. 2020;487:63–73.
Google ScholarÂ
Schultz DC, Ayyanathan K, Negorev D, Maul GG, Rauscher FJR. SETDB1: a novel KAP-1-associated histone H3, lysine 9-specific methyltransferase that contributes to HP1-mediated silencing of euchromatic genes by KRAB zinc-finger proteins. Genes Dev. 2002;16:919–32.
Google ScholarÂ
Wang H, An W, Cao R, Xia L, Erdjument-Bromage H, Chatton B, et al. MAM facilitates conversion by ESET of dimethyl to trimethyl lysine 9 of histone H3 to cause transcriptional repression. Mol Cell. 2003;12:475–87.
Google ScholarÂ
Nicetto D, Zaret KS. Role of H3K9me3 heterochromatin in cell identity establishment and maintenance. Curr Opin Genet Dev. 2019;55:1–10.
Google ScholarÂ
Tachibana M, Sugimoto K, Nozaki M, Ueda J, Ohta T, Ohki M, et al. G9a histone methyltransferase plays a dominant role in euchromatic histone H3 lysine 9 methylation and is essential for early embryogenesis. Genes Dev. 2002;16:1779–91.
Google ScholarÂ
Ogawa S, Fukuda A, Matsumoto Y, Hanyu Y, Sono M, Fukunaga Y, et al. SETDB1 inhibits p53-mediated apoptosis and is required for formation of pancreatic ductal adenocarcinomas in mice. Gastroenterology. 2020;159:682–96.
Google ScholarÂ
Alagoz M, Katsuki Y, Ogiwara H, Ogi T, Shibata A, Kakarougkas A, et al. SETDB1, HP1 and SUV39 promote repositioning of 53BP1 to extend resection during homologous recombination in G2 cells. Nucleic Acids Res. 2015;43:7931–44.
Google ScholarÂ
Ropa J, Saha N, Hu H, Peterson LF, Talpaz M, Muntean AG. SETDB1 mediated histone H3 lysine 9 methylation suppresses MLL-fusion target expression and leukemic transformation. Haematologica. 2020;105:2273–85.
Google ScholarÂ
Ceol CJ, Houvras Y, Jane-Valbuena J, Bilodeau S, Orlando DA, Battisti V, et al. The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset. Nature. 2011;471:513–7.
Google ScholarÂ
Yang W, Wei Y, Wang T, Xu Y, Jin X, Qian H, et al. Cytoplasmic localization of SETDB1‑induced warburg effect via c‑MYC‑LDHA axis enhances migration and invasion in breast carcinoma. Int J Mol Med. 2024;53:40.
Google ScholarÂ
Xiao J, Sun Q, Ding L, Chien W, Liu X, Mayakonda A, et al. The c-MYC-BMI1 axis is essential for SETDB1-mediated breast tumourigenesis. J Pathol. 2018;246:89–102.
Google ScholarÂ
Barral A, Pozo G, Ducrot L, Papadopoulos GL, Sauzet S, Oldfield AJ, et al. SETDB1/NSD-dependent H3K9me3/H3K36me3 dual heterochromatin maintains gene expression profiles by bookmarking poised enhancers. Mol Cell. 2022;82:816–32.
Google ScholarÂ
Padeken J, Methot SP, Gasser SM. Establishment of H3K9-methylated heterochromatin and its functions in tissue differentiation and maintenance. Nat Rev Mol cell Biol. 2022;23:623–40.
Google ScholarÂ
Adoue V, Binet B, Malbec A, Fourquet J, Romagnoli P, van Meerwijk JPM, et al. The histone methyltransferase SETDB1 controls t helper cell lineage integrity by repressing endogenous retroviruses. Immunity. 2019;50:629–44.
Google ScholarÂ
Markouli M, Strepkos D, Chlamydas S, Piperi C. Histone lysine methyltransferase SETDB1 as a novel target for central nervous system diseases. Prog Neurobiol. 2021;200:101968.
Google ScholarÂ
Kim Y, Wang SE, Jiang Y. Epigenetic therapy of prader-willi syndrome. Transl Res J Lab Clin Med. 2019;208:105–18.
Google ScholarÂ
Ma T, Xu F, Hou Y, Shu Y, Zhao Z, Zhang Y, et al. SETDB1: progress and prospects in cancer treatment potential and inhibitor research. Bioorg Chem. 2024;145:107219.
Google ScholarÂ
Johnson E, Salari K, Yang S. SETDB1: a perspective into immune cell function and cancer immunotherapy. Immunology. 2023;169:3–12.
Google ScholarÂ
Hassanie H, Penteado AB, de Almeida LC, Calil RL, Da Silva Emery F, Costa-Lotufo LV, et al. SETDB1 as a cancer target: challenges and perspectives in drug design. RSC Med Chem. 2024;15:1424–51.
Google ScholarÂ
Strepkos D, Markouli M, Klonou A, Papavassiliou AG, Piperi C. Histone methyltransferase SETDB1: a common denominator of tumorigenesis with therapeutic potential. Cancer Res. 2021;81:525–34.
Google ScholarÂ
Batham J, Lim PS, Rao S. SETDB-1: a potential epigenetic regulator in breast cancer metastasis. Cancers. 2019;11:1143.
Google ScholarÂ
Yang W, Su Y, Hou C, Chen L, Zhou D, Ren K, et al. SETDB1 induces epithelial‑mesenchymal transition in breast carcinoma by directly binding with snail promoter. Oncol Rep. 2019;41:1284–92.
Google ScholarÂ
Zakharova VV, Magnitov MD, Del Maestro L, Ulianov SV, Glentis A, Uyanik B, et al. SETDB1 fuels the lung cancer phenotype by modulating epigenome, 3D genome organization and chromatin mechanical properties. Nucleic Acids Res. 2022;50:4389–413.
Google ScholarÂ
Wu P, Lu J, Yang J, Lin I, Ou D, Lin Y, et al. H3K9 histone methyltransferase, KMT1E/SETDB1, cooperates with the SMAD2/3 pathway to suppress lung cancer metastasis. Cancer Res. 2014;74:7333–43.
Google ScholarÂ
Zhang E, He P. The function of histone methyltransferase SETDB1 and its roles in liver cancer. Front Cell Dev Biol. 2024;12:1500263.
Google ScholarÂ
Fei Q, Shang K, Zhang J, Chuai S, Kong D, Zhou T, et al. Histone methyltransferase SETDB1 regulates liver cancer cell growth through methylation of p53. Nat Commun. 2015;6:8651.
Google ScholarÂ
Wong C, Wei L, Law C, Ho DW, Tsang FH, Au SL, et al. Up-regulation of histone methyltransferase SETDB1 by multiple mechanisms in hepatocellular carcinoma promotes cancer metastasis. Hepatology. 2016;63:474–87.
Google ScholarÂ
Lee J, Zhou P. DCAFs, the missing link of the CUL4-DDB1 ubiquitin ligase. Mol Cell. 2007;26:775–80.
Google ScholarÂ
Jackson S, Xiong Y. CRL4s: the CUL4-RING E3 ubiquitin ligases. Trends Biochem Sci. 2009;34:562–70.
Google ScholarÂ
Nakagawa T, Xiong Y. X-linked mental retardation gene CUL4B targets ubiquitylation of H3K4 methyltransferase component WDR5 and regulates neuronal gene expression. Mol Cell. 2011;43:381–91.
Google ScholarÂ
Zou Y, Mi J, Cui J, Lu D, Zhang X, Guo C, et al. Characterization of nuclear localization signal in the N-terminus of CUL4B and its essential role in cyclin E degradation and cell cycle progression. J Biol Chem. 2009;284:33320–32.
Google ScholarÂ
Hu H, Yang Y, Ji Q, Zhao W, Jiang B, Liu R, et al. CRL4B catalyzes H2AK119 monoubiquitination and coordinates with PRC2 to promote tumorigenesis. Cancer Cell. 2012;22:781–95.
Google ScholarÂ
Huang W, Zhang J, Huo M, Gao J, Yang T, Yin X, et al. CUL4B promotes breast carcinogenesis by coordinating with transcriptional repressor complexes in response to hypoxia signaling pathway. Adv Sci. 2021;8:2001515.
Google ScholarÂ
Yang Y, Liu R, Qiu R, Zheng Y, Huang W, Hu H, et al. CRL4B promotes tumorigenesis by coordinating with SUV39H1/HP1/DNMT3A in DNA methylation-based epigenetic silencing. Oncogene. 2015;34:104–18.
Google ScholarÂ
Li Y, Wang X. The role of cullin4B in human cancers. Exp Hematol Oncol. 2017;6:17.
Google ScholarÂ
Fan Y, Huo X, Guo B, Zhang X, Yang Y, Lian J, et al. Cullin 4B-RING ubiquitin ligase targets IRGM1 to regulate Wnt signaling and intestinal homeostasis. Cell Death Differ. 2022;29:1673–88.
Google ScholarÂ
Tarpey PS, Raymond FL, O’Meara S, Edkins S, Teague J, Butler A, et al. Mutations in CUL4B, which encodes a ubiquitin E3 ligase subunit, cause an X-linked mental retardation syndrome associated with aggressive outbursts, seizures, relative macrocephaly, central obesity, hypogonadism, pes cavus, and tremor. Am J Hum Genet. 2007;80:345–52.
Google ScholarÂ
Zou Y, Liu Q, Chen B, Zhang X, Guo C, Zhou H, et al. Mutation in CUL4B, which encodes a member of cullin-RING ubiquitin ligase complex, causes X-linked mental retardation. Am J Hum Genet. 2007;80:561–6.
Google ScholarÂ
Bass J, Takahashi JS. Circadian integration of metabolism and energetics. Science. 2010;330:1349–54.
Google ScholarÂ
Takahashi JS. Transcriptional architecture of the mammalian circadian clock. Nat Rev Genet. 2017;18:164–79.
Google ScholarÂ
Partch CL, Green CB, Takahashi JS. Molecular architecture of the mammalian circadian clock. Trends Cell Biol. 2014;24:90–9.
Google ScholarÂ
Kim YH, Lazar MA. Transcriptional control of circadian rhythms and metabolism: a matter of time and space. Endocr Rev. 2020;41:707–32.
Google ScholarÂ
Liu X, Duan Z, Yu M, Liu X. Epigenetic control of circadian clocks by environmental signals. Trends Cell Biol. 2024;34:992–1006.
Google ScholarÂ
Reszka E, Przybek M, Muurlink O, Pepłonska B. Circadian gene variants and breast cancer. Cancer Lett. 2017;390:137–45.
Google ScholarÂ
Stevens RG, Brainard GC, Blask DE, Lockley SW, Motta ME. Breast cancer and circadian disruption from electric lighting in the modern world. CA Cancer J Clin. 2014;64:207–18.
Google ScholarÂ
Gonzalez-Aponte MF, Damato AR, Simon T, Aripova N, Darby F, Jeon MS, et al. Daily glucocorticoids promote glioblastoma growth and circadian synchrony to the host. Cancer Cell. 2025;43:144–60.
Google ScholarÂ
Pang L, Dunterman M, Xuan W, Gonzalez A, Lin Y, Hsu W, et al. Circadian regulator CLOCK promotes tumor angiogenesis in glioblastoma. Cell Rep. 2023;42:112127.
Google ScholarÂ
Motiei M, Abu-Dawud R, Relógio A, Assaf C. Circadian rhythms in haematological malignancies: therapeutic potential and personalised interventions. EBioMedicine. 2024;110:105451.
Google ScholarÂ
Sanford ABA, Da Cunha LS, Machado CB, de Pinho Pessoa FMC, Silva ANDS, Ribeiro RM, et al. Circadian rhythm dysregulation and leukemia development: the role of clock genes as promising biomarkers. Int J Mol Sci. 2022;23:8212.
Google ScholarÂ
Liu J, Xu X, Rixiati Y, Wang C, Ni H, Chen W, et al. Dysfunctional circadian clock accelerates cancer metastasis by intestinal microbiota triggering accumulation of myeloid-derived suppressor cells. Cell Metab. 2024;36:1320–34.
Google ScholarÂ
Zhu H, Chen J, Wen Z, Li J, Yu Q, Liao W, et al. The role of circadian clock genes in colorectal carcinoma: novel insights into regulatory mechanism and implications in clinical therapy. Life Sci. 2023;333:122145.
Google ScholarÂ
Anafi RC, Francey LJ, Hogenesch JB, Kim J. CYCLOPS reveals human transcriptional rhythms in health and disease. Proc Natl Acad Sci USA. 2017;114:5312–7.
Google ScholarÂ
Filipski E, King VM, Li X, Granda TG, Mormont M, Liu X, et al. Host circadian clock as a control point in tumor progression. J Natl Cancer Inst. 2002;94:690–7.
Google ScholarÂ
Wegrzyn LR, Tamimi RM, Rosner BA, Brown SB, Stevens RG, Eliassen AH, et al. Rotating night-shift work and the risk of breast cancer in the nurses’ health studies. Am J Epidemiol. 2017;186:532–40.
Google ScholarÂ
Chen S, Choo K, Hou M, Yeh K, Kuo S, Chang J. Deregulated expression of the PER1, PER2 and PER3 genes in breast cancers. Carcinogenesis. 2005;26:1241–6.
Google ScholarÂ
Zhang M, Liu Y, Shi L, Fang L, Xu L, Cao Y. Neural stemness unifies cell tumorigenicity and pluripotent differentiation potential. J Biol Chem. 2022;298:102106.
Google ScholarÂ
Mazzoccoli G, Colangelo T, Panza A, Rubino R, De Cata A, Tiberio C, et al. Deregulated expression of cryptochrome genes in human colorectal cancer. Mol Cancer. 2016;15:6.
Google ScholarÂ
Ji A, Li H, Fu X, Zhang Y, Liu Y. Long non-coding RNA NEAT1 induced by BHLHE40 activates Wnt/β-catenin signaling and potentiates colorectal cancer progression. Cell Div. 2024;19:25.
Google ScholarÂ
Kim Y, Jung Y, Kim T, Kim H. Alu-related transcript of TJP2 gene as a marker for colorectal cancer. Gene. 2013;524:268–74.
Google ScholarÂ
Guo Y, Mao X, Xiong L, Xia A, You J, Lin G, et al. Structure-guided discovery of a potent and selective cell-active inhibitor of SETDB1 Tudor domain. Angew Chem. 2021;60:8760–5.
Google ScholarÂ
Torrano J, Al Emran A, Hammerlindl H, Schaider H. Emerging roles of H3K9me3, SETDB1 and SETDB2 in therapy-induced cellular reprogramming. Clin Epigenet. 2019;11:43.
Google ScholarÂ
Micevic G, Bosenberg MW, Yan Q. The crossroads of cancer epigenetics and immune checkpoint therapy. Clin Cancer Res. 2023;29:1173–82.
Google ScholarÂ
Yu L, Ye F, Li Y, Zhan Y, Liu Y, Yan H, et al. Histone methyltransferase SETDB1 promotes colorectal cancer proliferation through the STAT1-CCND1/CDK6 axis. Carcinogenesis. 2020;41:678–88.
Google ScholarÂ
Luo F, Zhang M, Sun B, Xu C, Yang Y, Zhang Y, et al. LINC00115 promotes chemoresistant breast cancer stem-like cell stemness and metastasis through SETDB1/PLK3/HIF1α signaling. Mol Cancer. 2024;23:60.
Google ScholarÂ
Wang G, Long J, Gao Y, Zhang W, Han F, Xu C, et al. SETDB1-mediated methylation of akt promotes its K63-linked ubiquitination and activation leading to tumorigenesis. Nat Cell Biol. 2019;21:214–25.
Google ScholarÂ
Cao N, Yu Y, Zhu H, Chen M, Chen P, Zhuo M, et al. SETDB1 promotes the progression of colorectal cancer via epigenetically silencing p21 expression. Cell Death Dis. 2020;11:351.
Google ScholarÂ
Chen K, Zhang F, Ding J, Liang Y, Zhan Z, Zhan Y, et al. Histone methyltransferase SETDB1 promotes the progression of colorectal cancer by inhibiting the expression of TP53. J Cancer. 2017;8:3318–30.
Google ScholarÂ
Tian J, Wang W, Zhu J, Zhuang Y, Qi C, Cai Z, et al. Histone methyltransferase SETDB1 promotes immune evasion in colorectal cancer via FOSB-mediated downregulation of MicroRNA-22 through BATF3/PD-l1 pathway. J Immunol Res. 2022;2022:4012920.
Google ScholarÂ
Li W, Yang X, Liu X, Deng H, Li W, He X, et al. SETDB1 confers colorectal cancer metastasis by regulation of WNT/β-catenin signaling. Biochim Biophys Acta Gen Subj. 2023;1867:130377.
Google ScholarÂ
Griffin GK, Wu J, Iracheta-Vellve A, Patti JC, Hsu J, Davis T, et al. Epigenetic silencing by SETDB1 suppresses tumour intrinsic immunogenicity. Nature. 2021;595:309–14.
Google ScholarÂ
Yin X, Teng X, Ma T, Yang T, Zhang J, Huo M, et al. RUNX2 recruits the NuRD(MTA1)/CRL4B complex to promote breast cancer progression and bone metastasis. Cell Death Differ. 2022;29:2203–17.
Google ScholarÂ
Yang T, Huang W, Ma T, Yin X, Zhang J, Huo M, et al. The PRMT6/PARP1/CRL4B complex regulates the circadian clock and promotes breast tumorigenesis. Adv Sci. 2023;10:e2202737.
Google ScholarÂ
Hu T, Ma T, Huo M, Liu J, Zhang D, Li Y, et al. JAB1/CRL4B complex represses PPARG/ACSL5 expression to promote breast tumorigenesis. Cell Death Differ. 2025;33:1175–91.
Wang W, Zhang Z, Zhao M, Wang Y, Ge Y, Shan L. Zinc-finger protein CXXC5 promotes breast carcinogenesis by regulating the TSC1/mTOR signaling pathway. J Biol Chem. 2023;299:102812.
Google ScholarÂ
Leng S, Huang W, Chen Y, Yang Y, Feng D, Liu W, et al. SIRT1 coordinates with the CRL4B complex to regulate pancreatic cancer stem cells to promote tumorigenesis. Cell Death Differ. 2021;28:3329–43.
Google ScholarÂ
Qi M, Jiao M, Li X, Hu J, Wang L, Zou Y, et al. CUL4b promotes gastric cancer invasion and metastasis-involvement of upregulation of HER2. Oncogene. 2018;37:1075–85.
Google ScholarÂ
Qi M, Hu J, Cui Y, Jiao M, Feng T, Li X, et al. CUL4b promotes prostate cancer progression by forming positive feedback loop with SOX4. Oncogenesis. 2019;8:23.
Google ScholarÂ
Chen Z, Shen B, Fu Q, Wang F, Tang Y, Hou C, et al. CUL4B promotes proliferation and inhibits apoptosis of human osteosarcoma cells. Oncol Rep. 2014;32:2047–53.
Google ScholarÂ
Saw PE, Liu Q, Wong P, Song E. Cancer stem cell mimicry for immune evasion and therapeutic resistance. Cell Stem Cell. 2024;31:1101–12.
Google ScholarÂ
Batlle E, Clevers H. Cancer stem cells revisited. Nat Med. 2017;23:1124–34.
Google ScholarÂ
Bai X, Ni J, Beretov J, Graham P, Li Y. Cancer stem cell in breast cancer therapeutic resistance. Cancer Treat Rev. 2018;69:152–63.
Google ScholarÂ
Zhang Y, Zhang Q, Liu R, Zhang D, Hu G, Chen X. Circadian disruption in cancer and regulation of cancer stem cells by circadian clock genes: an updated review. Cancer Lett. 2024;611:217391.
Google ScholarÂ
Li G, Wan Y, Cui G, Jiang K, Su J, Duan S, et al. Cancer metastasis mediated by circadian rhythm disruption: molecular mechanisms to clinical significance and implications. Cancer Lett. 2026;638:218155.
Google ScholarÂ
Yuan G, Liu Y, Wu D, Xu J. PER3 suppresses lung adenocarcinomatous cell proliferation/migration through activating AMPK/mTOR pathway. Sci Rep. 2025;15:41605.
Google ScholarÂ
Li Q, Xia D, Wang Z, Liu B, Zhang J, Peng P, et al. Circadian rhythm gene PER3 negatively regulates stemness of prostate cancer stem cells via WNT/β-catenin signaling in tumor microenvironment. Front Cell Dev Biol. 2021;9:656981.
Google ScholarÂ
Wang X, Yan D, Teng M, Fan J, Zhou C, Li D, et al. Reduced expression of PER3 is associated with incidence and development of colon cancer. Ann Surg Oncol. 2012;19:3081–8.
Google ScholarÂ
Hong Z, Feng Z, Sai Z, Tao S. PER3, a novel target of mir-103, plays a suppressive role in colorectal cancer in vitro. BMB Rep. 2014;47:500–5.
Google ScholarÂ
Zhang F, Sun H, Zhang S, Yang X, Zhang G, Su T. Overexpression of PER3 inhibits self-renewal capability and chemoresistance of colorectal cancer stem-like cells via inhibition of notch and β-catenin signaling. Oncol Res. 2017;25:709–19.
Google ScholarÂ
Hasakova K, Vician M, Reis R, Zeman M, Herichova I. The expression of clock genes cry1 and cry2 in human colorectal cancer and tumor adjacent tissues correlates differently dependent on tumor location. Neoplasma. 2018;65:986–92.
Google ScholarÂ
Fortin BM, Pfeiffer SM, Insua-RodrÃguez J, Alshetaiwi H, Moshensky A, Song WA, et al. Circadian control of tumor immunosuppression affects efficacy of immune checkpoint blockade. Nat Immunol. 2024;25:1257–69.
Google ScholarÂ
